Current and emerging treatment options for uveal melanoma

Patricia Rusa Pereira,1 Alexandre Nakao Odashiro,2 Li-Anne Lim,1 Cristina Miyamoto,1 Paula L Blanco,4 Macanori Odashiro,3 Shawn Maloney,1 Dominique F De Souza,1 Miguel N Burnier Jr1 1The Henry C Witelson Ocular Pathology Laboratory, McGill University, Montreal, QC, Canada; 2Department of Pathology a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pereira PR, Odashiro AN, Lim L, Miyamoto C, Blanco PL, Odashiro M, Maloney S, De Souza DF, Burnier Jr MN
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/833383240330450a8440b68616be1d4e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:833383240330450a8440b68616be1d4e
record_format	dspace
spelling	oai:doaj.org-article:833383240330450a8440b68616be1d4e2021-12-02T07:16:31ZCurrent and emerging treatment options for uveal melanoma1177-54671177-5483https://doaj.org/article/833383240330450a8440b68616be1d4e2013-08-01T00:00:00Zhttp://www.dovepress.com/current-and-emerging-treatment-options-for-uveal-melanoma-a14131https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Patricia Rusa Pereira,1 Alexandre Nakao Odashiro,2 Li-Anne Lim,1 Cristina Miyamoto,1 Paula L Blanco,4 Macanori Odashiro,3 Shawn Maloney,1 Dominique F De Souza,1 Miguel N Burnier Jr1 1The Henry C Witelson Ocular Pathology Laboratory, McGill University, Montreal, QC, Canada; 2Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada; 3Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil; 4Department of Pathology and Laboratory Medicine, University of Ottawa, ON, Canada Abstract: Uveal melanoma (UM) is the most common primary malignant intraocular tumor in adults, with a 10-year cumulative metastatic rate of 34%. The most common site of metastasis is the liver (95%). Unfortunately, the current treatment of metastatic UM is limited by the lack of effective systemic therapy. Options for the management of the primary intraocular tumor include radical surgery as well as conservative treatments in order to preserve visual acuity. For metastatic disease, several approaches have been described with no standard method. Nevertheless, median survival after liver metastasis is poor, being around 4–6 months, with a 1-year survival of 10%–15%. In this review, the authors summarize current and promising new treatments for UM. Keywords: uveal melanoma, choroidal melanoma, eye, metastasis, treatment, therapyPereira PROdashiro ANLim LMiyamoto CBlanco PLOdashiro MMaloney SDe Souza DFBurnier Jr MNDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 1669-1682 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Pereira PR Odashiro AN Lim L Miyamoto C Blanco PL Odashiro M Maloney S De Souza DF Burnier Jr MN Current and emerging treatment options for uveal melanoma
description	Patricia Rusa Pereira,1 Alexandre Nakao Odashiro,2 Li-Anne Lim,1 Cristina Miyamoto,1 Paula L Blanco,4 Macanori Odashiro,3 Shawn Maloney,1 Dominique F De Souza,1 Miguel N Burnier Jr1 1The Henry C Witelson Ocular Pathology Laboratory, McGill University, Montreal, QC, Canada; 2Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada; 3Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil; 4Department of Pathology and Laboratory Medicine, University of Ottawa, ON, Canada Abstract: Uveal melanoma (UM) is the most common primary malignant intraocular tumor in adults, with a 10-year cumulative metastatic rate of 34%. The most common site of metastasis is the liver (95%). Unfortunately, the current treatment of metastatic UM is limited by the lack of effective systemic therapy. Options for the management of the primary intraocular tumor include radical surgery as well as conservative treatments in order to preserve visual acuity. For metastatic disease, several approaches have been described with no standard method. Nevertheless, median survival after liver metastasis is poor, being around 4–6 months, with a 1-year survival of 10%–15%. In this review, the authors summarize current and promising new treatments for UM. Keywords: uveal melanoma, choroidal melanoma, eye, metastasis, treatment, therapy
format	article
author	Pereira PR Odashiro AN Lim L Miyamoto C Blanco PL Odashiro M Maloney S De Souza DF Burnier Jr MN
author_facet	Pereira PR Odashiro AN Lim L Miyamoto C Blanco PL Odashiro M Maloney S De Souza DF Burnier Jr MN
author_sort	Pereira PR
title	Current and emerging treatment options for uveal melanoma
title_short	Current and emerging treatment options for uveal melanoma
title_full	Current and emerging treatment options for uveal melanoma
title_fullStr	Current and emerging treatment options for uveal melanoma
title_full_unstemmed	Current and emerging treatment options for uveal melanoma
title_sort	current and emerging treatment options for uveal melanoma
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/833383240330450a8440b68616be1d4e
work_keys_str_mv	AT pereirapr currentandemergingtreatmentoptionsforuvealmelanoma AT odashiroan currentandemergingtreatmentoptionsforuvealmelanoma AT liml currentandemergingtreatmentoptionsforuvealmelanoma AT miyamotoc currentandemergingtreatmentoptionsforuvealmelanoma AT blancopl currentandemergingtreatmentoptionsforuvealmelanoma AT odashirom currentandemergingtreatmentoptionsforuvealmelanoma AT maloneys currentandemergingtreatmentoptionsforuvealmelanoma AT desouzadf currentandemergingtreatmentoptionsforuvealmelanoma AT burnierjrmn currentandemergingtreatmentoptionsforuvealmelanoma
_version_	1718399523764568064

Current and emerging treatment options for uveal melanoma

Ejemplares similares